SUBSCRIBERS
J&J drug unit to leverage Singapore's biotech hub
'Very lively biotech hub' spurs pharmaceutical arm's external collaborations
Annabeth Leow
Published Sun, Oct 28, 2018 · 09:50 PM
Singapore
JOHNSON & Johnson's (J&J) regional pharmaceutical head believes that Singapore offers innovation, research and development tie-up opportunities, even as wider insurance coverage in the Asia-Pacific is expected to fuel growth for drugmakers.
Ong Ai Hua, the group chairman for Janssen Asia Pacific, the pharmaceutical arm of J&J, told The Business Times that "our focus in Singapore is on innovation - not so much on manufacturing".
Copyright SPH Media. All rights reserved.
